Merck raises its 2026 revenue outlook to as much as $67.3 billion but cuts its profit guidance

Merck reported better than expected second quarter results on Tuesday 4 August 2026. According to CNBC, revenue rose 5% to $16.61 billion against a forecast of $16.36 billion, and the adjusted loss per share was 13 cents versus 27 cents expected.

The company raised its 2026 revenue outlook to a range of $66.3 billion to $67.3 billion, up from a previous $65.8 billion to $67 billion. It cut its adjusted earnings guidance to between $2.66 and $2.76 per share from a previous $5.04 to $5.16, with the new range including a one time charge of $5.7 billion tied to its acquisition of Terns Pharmaceuticals and a $9 billion charge related to its January purchase of Cidara Therapeutics.

Sales of Keytruda rose 5% to $8.37 billion, including $463 million from the new injectable version. Winrevair sales rose 75% to $588 million and the pneumococcal vaccine Capvaxive booked $184 million, up 42% year on year.